Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-Receptor LAG-3 for Enhanced Anti-Tumor Immunity

Cell Reports - United States
doi 10.1016/j.celrep.2020.01.076
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

LAG-3 and PD-1+LAG-3 Inhibition Promote Anti-Tumor Immune Responses in Human Autologous Melanoma/T Cell Co-Cultures

OncoImmunology
OncologyAllergyImmunology
2020English

Author Correction: The Yin and Yang of Co-Inhibitory Receptors: Toward Anti-Tumor Immunity Without Autoimmunity

Cell Research
Cell BiologyMolecular Biology
2020English

Tim-3 and Its Role in Regulating Anti-Tumor Immunity

Immunological Reviews
AllergyImmunology
2017English

Expression of LAG-3 and Efficacy of Combination Treatment With Anti-Lag-3 and Anti-Pd-1 Monoclonal Antibodies in Glioblastoma

International Journal of Cancer
Cancer ResearchOncology
2018English

Inhibition of 14-3-3/Tau by Hybrid Small-Molecule Peptides Operating via Two Different Binding Modes

English

Lung Adenocarcinoma-Intrinsic GBE1 Signaling Inhibits Anti-Tumor Immunity

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2019English

Distinct Roles of GSK-3 and GSK-3 Phosphorylation in the Heart Under Pressure Overload

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Cell
BiochemistryGeneticsMolecular Biology
2019English

GSK-3 Inhibitors: Anti-Diabetic Treatment Associated With Cardiac Risk?

Cardiovascular Drugs and Therapy
MedicineCardiovascular MedicinePharmacologyCardiology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy